Neoadjuvant chemotherapy (NAC) has become a standard of care not only in locally advanced breast cancer, but in early breast cancer, especially for patients with large tumor size, lymph node metastasis, HER2 overexpression and triple negative breast cancer (TNBC) subtype. Here, ERBB2 is linked to breast cancer.